Error loading player: No playable sources found

AM24-SN-06-O

AM24-SN-06-O: Operationalizing Delivery of Gene Therapy for Sickle Cell Disease (Enduring)

Date
October 23, 2024
Credits
1 General Continuing Education (GEN) | 1 Florida Lab Personnel (FLP) | 1 California Nurse (CN) | 1 California Lab Personnel (CLP) | 1 Physician (PHY)
$30
Standard Price
Members save $5
This product is also available as part of the following products:
Thumbnail for 2024 AABB Annual Meeting On-Demand: BIOTHERAPIES SESSIONS
Interested in all sessions Cellular Therapy/Biotherapies? Then this is the package for you. We have also thrown in a couple of additional sessions you might also find interesting…
Thumbnail for 2024 AABB Annual Meeting On-Demand: CABP CE Eligible Sessions
Interested in sessions eligible to maintain your AABB Certified Advanced Biotherapies Professional (CABP) certification? This package provides:
Thumbnail for 2024 Annual Meeting On-Demand: FULL ACCESS
By far the best value to watch all the on-demand educational sessions from the 2024 AABB Annual Meeting and earn continuing education credit…

CABP CE Eligible

This session focuses on new FDA-approved gene therapies for sickle cell disease (SCD) and the critical aspects of coordinating care for gene therapy, including an approach to transfusion support and maximizing stem cell collections. With recent advancements in gene therapy offering a cure for SCD, effective coordination among multidisciplinary healthcare teams is essential to ensure optimal patient outcomes. Barriers to offering gene therapy for SCD may include alloimmunization to multiple antigens and an inability to collect sufficient autologous hematopoietic stem cells. The session will delve into the details of patient selection, pre-treatment assessments, treatment protocols, and coordination of complex care. Participants will have the opportunity to engage in discussions, case presentations, and a Q&A session with experts in the field of sickle cell disease, gene therapy and transfusion support. The session aims to share best practices and practical strategies for integrating gene therapy into the care plan for patients with SCD at both adult and pediatric institutions.

Learning Objectives

  • Review current FDA approved gene therapies and criteria for identifying suitable candidates
  • Discuss an approach to multidisciplinary care coordination with hematologists, transfusion and transplant specialists, and psychologists
  • Discuss an approach to safe transfusion support, particularly for those that may be difficult to match
  • Review and familiarize practitioners with stem cell mobilization and technical aspects of collections to enhance stem cell yield for patients with SCD

Moderator

Speaker Image for Ryan Metcalf
Section Chief, Transfusion Medicine, ARUP Labs and Utah School of Medicine

Speakers

Speaker Image for Stella Chou
Children's Hospital of Philadelphia, University of Pennsylvania
Speaker Image for Yan Zheng
Yan Zheng, MD, PhD
Assistant Member, St. Jude Children's Research Hospital

Related Products

Thumbnail for AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)
AM24-MN-32-O: Lyophilized, Stem-cell Derived, and Synthetic Platelet Products are Closer Than You May Think (Enduring)
This session will highlight advances in three areas of platelet research; stabilization methods through lyophilization, iPSC ex-vivo production, and synthetic nanoparticle technology are converging and can lead to long-lived platelet-based therapies targeted to address specific related pathologies…
Thumbnail for AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection?  Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate (Enduring)
AM24-TU-10-O: Is Your Firm Ready for an FDA Office of Inspections and Investigations Inspection? Hear about the Most Frequently Cited Observations and Inspectional Process from FDA’s Office of Biologics Inspectorate (Enduring)
This informative session will give an overview of inspections conducted by FDA’s Office of Inspections and Investigations (OII), Office of Biologics Inspectorate (OBI), including OBI’s role in regulatory inspections and current regulatory oversight…
Thumbnail for AM24-MN-34-O: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation (Enduring)
AM24-MN-34-O: Mechanisms and Technologies Towards Expanding Hematopoietic Stem Cells for Transplantation (Enduring)
Hematopoietic stem cells (HSCs) are the apex hematopoietic cell with the potential to produce robust and lifelong production of all blood cells. Thus, understanding the details of HSC molecular biology is critical to our understanding of human health and longevity…
Thumbnail for AM24-TU-03-O: Addressing Racial Disparities Across Donation Products for Marginalized Peoples (Enduring)
AM24-TU-03-O: Addressing Racial Disparities Across Donation Products for Marginalized Peoples (Enduring)
Despite the need for diverse donors of blood, stem cells, and organs/tissues, such donors remain dramatically underrepresented in donor pools, across donation products.. This session will begin with a brief didactic component, where expert presenters (Dr…